Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (April 2016)
28 slides from Prescient Therapeutics's investor presentation, Apr 13, 2016
Slide 1: Blue chip US science yielding a deep clinical pipeline
Blue chip US science yielding For personal use only a deep clinical pipeline » Spotlight on AML ahead of imminent Phase 1b/2 trial April 2016
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor For personal use only Certain statements made in this presentation are forward-looking statements within the meaning of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical fa
Slide 3: Investment Summary: Why all the excitement about AML?
Investment Summary: Why all the excitement about AML? For personal use only • Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need. » One of the worst survival rates of all cancers » Standard of care unchanged in 40 years • A disease of intense interest for clinicians, pharma co
Slide 4: Deep, Clinical Stage Product Pipeline
Deep, Clinical Stage Product Pipeline For personal use only PTX has one of the deepest and most mature product pipelines on ASX Discovery Screening Preclinical Phase 1 Phase 1b Phase 2 Phase 3 PTX-200 Breast Cancer Finishing PTX-200 Ovarian Cancer Underway PTX-200 AML 1H 2016 PTX-100 Breast Cancer P
Slide 5: Corporate Snapshot
Corporate Snapshot For personal use only Key Metrics Shareholder Base ASX Ticker PTX Total Issued Capital 93.7 M shares Board & 4.3 M Management: 14% Options (ex A$0.10; exp 12 Oct 2017) Share Price1 A$0.10 Market Capitalisation1 A$9.3 M Cash Position2 A$2.4 M Top 20 Own 33% 6 month turnover1 30 M s
Slide 6: Underpinned by extensive peer reviewed work
Underpinned by extensive peer reviewed work Science validated by >65 peer reviewed publications, including: For personal use only 6
Slide 7: PTX's valuation obviously doesn't weigh up!
PTX’s valuation obviously doesn’t weigh up! For personal use only >$20 M Prestigious already Two novel invested Technology technology founders platforms targeting Akt and Ras/Rho inhibition Mechanism 4 INDs of Action well open understood Phase 1b ovarian Phase 1b/2 …and a current trial recruiting -
Slide 8: How Our Drugs Work: "Molecular Switches"
How Our Drugs Work: “Molecular Switches” For personal use only Akt & Ras are growth factors PTX’s drugs block the found in cancer cells – Akt & Ras growth signals, when they are turned on, switching the growth signals they send a signal to the off and causing the cancer cancer cell to grow cell to d
Slide 9: Akt is an important drug target
Akt is an important drug target • Akt pathway promotes cellular survival and growth For personal use only PTX-00 (TCN-P) • Hyperactive Akt signaling has two deleterious effects: » Plays key role in the development of many cancers including breast, ovarian, colorectal, prostate, pancreatic and hemato
Slide 10: PTX-200: Novel Akt inhibition
PTX-200: Novel Akt inhibition For personal use only • A small molecule inhibitor of the Akt signaling pathway PTX-200 (TCN-P) • Inhibits Akt without the toxicity of other attempts • Anti-proliferative AND pro-apoptotic • Novel mechanism of action » NOT an ATP mimic; not a direct kinase inhibitor » I
Slide 11: What is Chemoresistance?
What is Chemoresistance? For personal use only • Despite the many advances in cancer treatment over many decades, 90% of advanced cancer patients become resistant to chemotherapy • Resistance comes about when some of the cells that are not killed by the chemotherapy mutate (change) and become resist
Slide 12: World Class Centers & Collaborations
World Class Centers & Collaborations For personal use only New York Florida Previous clinical trials conducted at: 12
Slide 13: Working with the Moffitt Cancer Center
Working with the Moffitt Cancer Center For personal use only • H. Lee Moffitt Cancer Center & Research 1 2 Institute, established in 1986 in Tampa, Florida • 3rd largest cancer centre in the US • On one side of the campus is a world- leading “comprehensive cancer clinic” (1) » offering patients medi
Slide 14: Drugs don't develop themselves!
Drugs don’t develop themselves! • Proven success from discovery and clinical development through to FDA approvals. For personal use only • Professor and Chair, Department of Drug Discovery - Moffitt Cancer Center Said Sebti, PhD • Co-Program Leader, Chemical Biology and Molecular Medicine - Moffitt
Slide 15: Management and Board of Directors
Management and Board of Directors For personal use only • Experienced, complementary, and collaborative Steven • 16 years’ experience in healthcare investment banking Yatomi-Clarke • Collaborator on clinical trials conducted in Australia and the US in cancer CEO & Managing immunotherapy Director • B
Slide 16: World Class Scientific Advisory Board
World Class Scientific Advisory Board • Genuine international authorities, with particularly strong expertise in leukemia For personal use only • Professor of Oncologic Sciences, H. Lee Moffitt Cancer Center and University South Florida Jeff Lancet, • Section Chief of Leukemia in the Department of M
Slide 17: Acute Myeloid Leukemia Market Overview
Acute Myeloid Leukemia Market Overview For personal use only • AML is a type of cancer that affects the blood and bone marrow » Patient cannot produce normal blood cells » Blood cells cannot function properly nor fight disease • Progresses very quickly & 5 year survival is a dismal 25% • More common
Slide 18: Relevance of Akt in AML
Relevance of Akt in AML For personal use only • Frequent constitutive Akt activation (phosphorylation) in AML » Constitutive phosphorylation (Ser473 and Thr308) of Akt in AML compared to normal bone marrow cells in 44 out 66 of patients (72 %) • Implications for Akt as a modulator of chemotherapy re
Slide 19: PTX-200 synergizes cytarabine in AML cells
PTX-200 synergizes cytarabine in AML cells For personal use only • PTX-200 highly synergistic with cytarabine current standard of care in AML cells » PTX-200 + cytarabine = much more effective effect than the simple additive effect of either compound (i.e. 1 + 1 ≥ 2) • As cytarabine is the current s
Slide 20: PTX-200: Completed Phase I in AML (monotherapy)
PTX-200: Completed Phase I in AML (monotherapy) For personal use only Patients 32 Trial Centers MD Anderson & Moffitt Patient Advanced hematologic malignancies (mainly AML) Inclusion Administration 1 hour IV infusion on days 1, 8, and 15. Methods Cycles repeated every 21 days. Study To establish dos
Slide 21: PTX-200 reduced p-Akt in AML blasts
PTX-200 reduced p-Akt in AML blasts For personal use only • High p-AKT cells more sensitive to PTX-200 » p-Akt/AKT in AML » Action of PTX-200 on Akt samples before therapy phosphorylation in AML blasts 21 Lancet, et al. Leuk Res 2013; 37:1461
Slide 22: Compelling evidence for PTX-200 in AML
Compelling evidence for PTX-200 in AML For personal use only Efficacy hypothesis PTX-200 Evidence • High p-Akt is correlated with inferior survival in AML. • PTX-200 decreased pAKT in AML blasts. • Inhibiting p-Akt improves response to chemo in the • PTX-200 decreased pAKT in AML blasts, suggesting
Slide 23: Spectacular rise of Celator Pharmaceuticals
Spectacular rise of Celator Pharmaceuticals For personal use only •. Celator (NASDAQ: CPXX) soared to ~$780M valuation on positive Phase III data in AML (naïve/newly diagnosed secondary AML) • Reformulation of existing standard of care (liposomal cytarabine + daunorubicin) • Jeff Lancet was the Prin
Slide 24: Phase 1b Trial imminent: Acute Myeloid Leukemia
Phase 1b Trial imminent: Acute Myeloid Leukemia For personal use only . • PTX-200 plus cytarabine in refractory or relapsed AML • Phase 1 results very encouraging • Phase 1b/2 IND recently allowed by FDA • Jeff Lancet at Moffitt Cancer Center leading the trial Jeffrey E Lancet, M.D. Principal Invest
Slide 25: Pipeline Yielding Multiple Layers of Value
Pipeline Yielding Multiple Layers of Value For personal use only • Edison Investment Research: Sum-of-parts valuation DCF valuation • Risk-adjusted valuation of $0.53 per share ($0.45 fully diluted) rNPV rNPV/share (A$ M) (A$) Breast cancer (PTX-200) $13.9 M $0.15 Ovarian cancer (PTX-200) $5.4 M $0.
Slide 26: Catalysts To Watch Out For
Catalysts To Watch Out For For personal use only 1H 2016 2H 2016 1H 2017 2H 2017 Phase Ib expansion Breast Complete Phase Ib cancer Initiate Phase II Phase Ib dose escalation and interim Ovarian analysis cancer Complete Phase Ib IND allowed by US FDA Acute Initiate Phase Ib Myeloid Leukemia Dose e
Slide 27: Investment decision funnel for any biotech
Investment decision funnel for any biotech For personal use only Is the drug in a clinical trial, or still pre-clinical? 3 clinical trials Is the trial conducted to US FDA standard? 4 INDs under US FDA Do the indications make clinical & Targeting unmet/poorly met medical commercial sense? need
Slide 28: Contact
For personal use only Contact Steven Yatomi-Clarke CEO & Managing Director Prescient Therapeutics Limited E: steven@ptxtherapeutics.com M: +61 417 601 440 ptxtherapeutics.com
Prescient Therapeutics — Investor Presentation (April 2016) on 6ix